Log in
OTCMKTS:IMUN

Immune Therapeutics Stock Forecast, Price & News

$0.02
0.00 (0.00 %)
(As of 09/25/2020 12:00 AM ET)
Add
Compare
Today's Range
$0.02
Now: $0.02
$0.02
50-Day Range
$0.01
MA: $0.02
$0.02
52-Week Range
$0.00
Now: $0.02
$0.05
Volume348,735 shs
Average Volume1.44 million shs
Market Capitalization$7,476.00
P/E RatioN/A
Dividend YieldN/A
Beta0.66
Immune Therapeutics, Inc., together with its subsidiaries, focuses on the development and commercialization of therapeutic treatments for cancer, human immunodeficiency virus (HIV)/AIDS, and autoimmune and immune disorders in the United States and internationally. It develops methionine enkephalin IRT-101, a small synthetic pentapeptide; and low-dose naltrexone IRT-103, an opioid receptor antagonist that stimulates and/or regulates the immune system to treat a range of autoimmune diseases, including multiple sclerosis; immune disorders, such as Crohn's disease and cancer; and viral infections comprising HIV/AIDS. The company was formerly known as TNI BioTech, Inc. and changed its name to Immune Therapeutics, Inc. in December 2014. Immune Therapeutics, Inc. is headquartered in Orlando, Florida.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.58 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:IMUN
CUSIPN/A
Phone888-613-8802

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$110,000.00
Book Value($30.76) per share

Profitability

Net Income$-3,400,000.00
Return on Assets-20,660.61%

Miscellaneous

Employees4
Market Cap$7,476.00
Next Earnings Date11/17/2020 (Estimated)
OptionableNot Optionable
$0.02
0.00 (0.00 %)
(As of 09/25/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IMUN News and Ratings via Email

Sign-up to receive the latest news and ratings for IMUN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Immune Therapeutics (OTCMKTS:IMUN) Frequently Asked Questions

How has Immune Therapeutics' stock price been impacted by COVID-19?

Immune Therapeutics' stock was trading at $0.0064 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, IMUN stock has increased by 162.5% and is now trading at $0.0168.
View which stocks have been most impacted by COVID-19
.

When is Immune Therapeutics' next earnings date?

Immune Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 17th 2020.
View our earnings forecast for Immune Therapeutics
.

How were Immune Therapeutics' earnings last quarter?

Immune Therapeutics Inc (OTCMKTS:IMUN) issued its earnings results on Friday, August, 14th. The company reported ($1.76) earnings per share (EPS) for the quarter.
View Immune Therapeutics' earnings history
.

Are investors shorting Immune Therapeutics?

Immune Therapeutics saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 22,500 shares, an increase of 58.5% from the August 31st total of 14,200 shares. Based on an average daily volume of 355,100 shares, the days-to-cover ratio is currently 0.1 days.
View Immune Therapeutics' Short Interest
.

Who are some of Immune Therapeutics' key competitors?

What other stocks do shareholders of Immune Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Immune Therapeutics investors own include Northwest Biotherapeutics (NWBO), Arch Therapeutics (ARTH), Amerigo Resources (ARREF), Blue Apron (APRN), Africa Oil (AOIFF), Amarin (AMRN), AK Steel (AKS), Asanko Gold (AKG), Argitek (AGTK) and Agenus (AGEN).

Who are Immune Therapeutics' key executives?

Immune Therapeutics' management team includes the following people:
  • Ms. Noreen Griffin, Founder, CEO, Pres & Director (Age 66)
  • Mr. Peter Aronstam, Chief Financial Officer (Age 67)
  • Dr. Fengping Shan, Chief Science Officer (Age 60)
  • Dr. Angus George Dalgleish, Chief Medical Officer and Director of R&D (Age 69)
  • Dr. Joseph M. Fortunak, VP of Global R&D and Chemical Devel. (Age 64)

What is Immune Therapeutics' stock symbol?

Immune Therapeutics trades on the OTCMKTS under the ticker symbol "IMUN."

How do I buy shares of Immune Therapeutics?

Shares of IMUN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Immune Therapeutics' stock price today?

One share of IMUN stock can currently be purchased for approximately $0.02.

How big of a company is Immune Therapeutics?

Immune Therapeutics has a market capitalization of $7,476.00 and generates $110,000.00 in revenue each year. Immune Therapeutics employs 4 workers across the globe.

What is Immune Therapeutics' official website?

The official website for Immune Therapeutics is www.immunetherapeutics.com.

How can I contact Immune Therapeutics?

Immune Therapeutics' mailing address is 37 NORTH ORANGE AVENUE SUITE 800M, WINTER PARK FL, 32792. The company can be reached via phone at 888-613-8802.

This page was last updated on 9/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.